Barnard E A, Henley J M
MRC Molecular Neurobiology Unit, MRC Centre, Cambridge, UK.
Trends Pharmacol Sci. 1990 Dec;11(12):500-7. doi: 10.1016/0165-6147(90)90051-9.
In this article in the TiPS series on the pharmacology of excitatory amino acids Eric Barnard and Jeremy Henley report on the very recent advances in protein purification and molecular biology of their receptors. Although the NMDA receptor, which is the best characterized of these pharmacologically, has not yet yielded to recombinant DNA technology, several different clones encoding subunits of non-NMDA excitatory amino acid receptors have been reported. From the properties of these and of a purified non-NMDA receptor, and the pharmacology of the native responses to AMPA and kainate, the authors conclude that multiple non-NMDA subtypes exist and that one of these is a unitary receptor that can respond to both kainate and AMPA.
在《药理学与治疗学进展》(TiPS)系列中关于兴奋性氨基酸药理学的这篇文章里,埃里克·巴纳德和杰里米·亨利报道了其受体在蛋白质纯化和分子生物学方面的最新进展。尽管在药理学上特征最明确的N-甲基-D-天冬氨酸(NMDA)受体尚未通过重组DNA技术得到,但已有报道称有几个不同的克隆编码非NMDA兴奋性氨基酸受体的亚基。根据这些亚基以及纯化的非NMDA受体的特性,还有对α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)和海人藻酸天然反应的药理学研究,作者得出结论,存在多种非NMDA亚型,其中一种是能对海人藻酸和AMPA都产生反应的单一受体。